Dasselta 5 mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Dasselta 5 mg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Dasselta 5 mg

Quick Facts: Dasselta 5 mg

Property Description
Active ingredient Desloratadine
Form Film-coated tablet
Pharmacological class H₁-receptor antagonist (Antihistamine)
Common purpose Systemic relief from allergy-related discomfort
Origin Synthetic, derived from Loratadine

What Type of Medicine is Dasselta 5 mg?

Dasselta 5 mg is fundamentally categorized as a non-sedating, long-acting histamine antagonist with selective peripheral H₁-receptor activity. Its active ingredient, Desloratadine, is the major active metabolite of the older antihistamine, Loratadine. This classification places it among modern anti-allergy compounds that are refined to act predominantly outside the central nervous system. This distinction is key, as Desloratadine is designed to act directly with a favorable profile, supporting its use for relieving discomfort associated with common allergy exposure. The characteristics of Desloratadine result in effective symptom control with a minimal risk of drowsiness.

Composition and General Purpose

The product is a single-ingredient medicine, with its core therapeutic substance being Desloratadine contained within a film-coated tablet for oral administration. The physiological action of Desloratadine involves selective histamine H₁-receptor blockade, a mechanism that works by preventing the inflammatory chemical histamine from binding to and activating its corresponding receptors. This action interrupts the biological process that drives allergic symptoms. Therefore, the medicine's general purpose is to provide systemic relief by mitigating the body's overreaction to various allergens.

Regulatory References

  1. European Medicines Agency (EMA)
Advertisements

What side effects are possible with Dasselta 5 mg?

Possible Side Effects and Safety Information

Dasselta (desloratadine 5 mg) is generally well tolerated, with most adverse reactions being mild. Official regulatory documents categorize side effects primarily by frequency observed in clinical trials and post-marketing experience.


Common Adverse Reactions

Side effects reported as Common (occurring in up to 1 in 10 patients) in clinical trials for the 5 mg dose include:

  • Fatigue
  • Dry mouth
  • Headache

Serious and Rare Adverse Reactions

Adverse reactions reported in post-marketing surveillance are typically classified as Very Rare (may affect up to 1 in 10,000 people) or Not Known. Serious reactions include:

  • Hypersensitivity Reactions: Including anaphylaxis (severe allergic reaction), angioedema (swelling of the face, lips, or tongue), rash, and pruritus (itching).
  • Hepatobiliary Disorders: Liver enzyme elevations, increased bilirubin, and hepatitis (liver inflammation).
  • Nervous System Effects: Seizures, psychomotor hyperactivity, dizziness, somnolence, and hallucinations.
  • Cardiac Disorders: Palpitations and tachycardia (fast heartbeat).

Safety Considerations and Restrictions

Special Caution: The medication should be used with caution in individuals with a medical or familial history of seizures due to increased susceptibility. Additionally, caution is advised for patients with severe renal impairment.

Pregnancy and Breast-feeding: Use of Dasselta is generally not recommended during breast-feeding, as the active substance is excreted in human milk. Although large amounts of data indicate no malformative or fetal/neonatal toxicity, it is preferable to avoid use during pregnancy as a precautionary measure.

Mental Alertness: Although most individuals do not experience drowsiness, patients should be advised to establish their individual response before engaging in activities requiring full mental alertness, such as driving or operating machinery, due to the very rare potential for somnolence.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation on Desloratadine overdose establishes that the adverse event profile observed following exposure is generally similar to that seen with therapeutic doses, although the magnitude of the effects can be higher. The most commonly cited clinical manifestation of overdosage in regulatory summaries is drowsiness (somnolence). Clinical trials involving patient exposure to doses up to nine times the typical 5 mg amount (45 mg) have demonstrated no clinically relevant effects.


When to Seek Immediate Medical Help

Urgent medical attention is mandated by regulatory authorities if severe clinical signs occur. Immediate contact with emergency services (e.g., 911) is required if the patient has experienced a seizure, is exhibiting signs of collapse, has trouble breathing, or can’t be awakened. Furthermore, any suspected or accidental overdose necessitates immediate notification of a doctor, pharmacist, or nurse, and prompt contact with a Poison Control Helpline.


Official Overdose Management

Regulatory guidelines state that symptomatic and supportive treatment is recommended in the event of overdosage. Clinicians may consider standard measures to remove unabsorbed active substance from the body. It is noted in the official prescribing information that Desloratadine is not eliminated by haemodialysis, and critically, there is no specific antidote known to reverse the effects of the drug.

Advertisements

Therapeutic Uses of Dasselta 5 mg

What Dasselta 5 mg Treats: Main Uses and Benefits

Dasselta 5 mg (Desloratadine) is used to provide symptomatic relief for allergic distress, helping patients manage discomfort caused by reactions to environmental triggers. It is used for specific allergic conditions where additional support is required for episodic or fluctuating manifestations.

The application of this medication is primarily focused on easing symptoms related to the nose, eyes, and skin, most notably in cases of Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Chronic Idiopathic Urticaria (CIU).


Managing Symptoms of Allergic Rhinitis

This medication is applied to ease the cluster of symptoms associated with Allergic Rhinitis. It offers supportive relief by addressing persistent nasal symptoms (sneezing, runny nose, itching, and congestion) and ocular manifestations such as itchy or watery eyes. It contributes to easing the overall symptom load during periods of high allergen exposure.

Dasselta 5 mg helps address symptom clusters that may become intense or disruptive, especially when they interfere with daily comfort.


Supporting Management of Chronic Hives (Urticaria)

Dasselta 5 mg is also used in managing the cutaneous (skin) symptoms of Chronic Idiopathic Urticaria (CIU), a condition characterized by recurrent hives and persistent itching. Its application is relevant for easing symptoms related to persistent pruritus (itching) and helping with the management of wheals (raised skin eruptions). This assists with maintaining functional stability and supports general well-being during symptomatic phases.


Quick Fact: Support for Symptomatic Relief

Area of Use Symptom Relief Focus Patient Benefit
Allergic Rhinitis Nasal and ocular symptoms (itching, running, sneezing) Helps patients cope with symptom fluctuations.
Chronic Urticaria Skin itching (pruritus) and hive outbreaks (wheals) Supports the patient during symptomatic episodes by easing distress.

Regulatory References

  1. NIH DailyMed overview
Advertisements

Eligibility and Restrictions for Use

Dasselta 5 mg tablets are officially established for use in adults and adolescents aged 12 years and older. Eligibility for the medicine is defined by strict regulatory parameters concerning age, physiological state, and existing medical conditions.

Contraindicated Populations

The medicine is contraindicated in patients with a known hypersensitivity to the active substance desloratadine, any non-active ingredients, or the parent compound, loratadine. Use is also prohibited for patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption due to excipient content.

Populations with Use Restrictions

Population Group Eligibility Status Basis for Restriction
Children under 12 years Not Recommended Safety and efficacy have not been established for the 5 mg tablet dose.
Pregnant women Not Recommended Preferable to avoid use as safe use during pregnancy has not been formally established.
Breastfeeding women Not Recommended Desloratadine is excreted into breast milk.
Severe Renal Impairment Conditional Use Specific regulatory recommendation for reduced dosage applies.
Hepatic Impairment Conditional Use Specific regulatory recommendation for reduced dosage applies.

Patients with a medical or familial history of seizures should use the medicine with caution, as specified in regulatory documentation.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Desloratadine (Dasselta 5 mg) consistently describe a drug-drug interaction profile with a low incidence of clinically relevant effects. Based on controlled clinical pharmacology studies, no substance is formally listed as contraindicated for co-administration due to interaction risks.

Documented Pharmacokinetic Interactions

Co-administration with specific medicines results in pharmacokinetic changes, specifically increased plasma concentrations (C max and AUC) of desloratadine and its major metabolite. Substances involved include:

Interacting Substance Official Effect on Exposure Clinical Relevance
Ketoconazole Increased plasma concentration No clinically relevant safety change
Erythromycin Increased plasma concentration No clinically relevant safety change
Azithromycin / Cimetidine Increased plasma concentration Not classified as clinically significant

Regulatory assessments confirm that despite these documented exposure modifications, controlled studies showed no corresponding clinically relevant changes in the overall safety profile when these substances were co-administered. No mandatory timing-based separation rules are documented for these interactions.

Interaction Status with Food and Alcohol

The medicine may be taken with or without a meal, as food does not significantly affect the absorption of Desloratadine. In formal clinical trials, Desloratadine did not potentiate the performance-impairing effects of alcohol. However, post-marketing surveillance includes official reports of alcohol intolerance and intoxication. Furthermore, regulatory labeling notes that patients with severe renal impairment or hepatic impairment experience slower clearance, leading to significantly higher systemic exposure of Desloratadine.

Advertisements

Mechanism of Action

Dasselta, through its primary active metabolite desloratadine, functions as a selective peripheral H1 receptor antagonist. This interaction constitutes a competitive inhibition at the receptor site, ensuring that the pharmacological agent remains bound to the biochemical target. The molecular structure is designed to minimize its passage across the blood-brain barrier, maintaining activity primarily in peripheral tissues.

By occupying the H1 receptor, Dasselta prevents endogenous histamine from binding and activating the receptor. This molecular blockade effectively attenuates the G-protein-coupled signaling cascade normally initiated upon H1 activation. This action subsequently modulates the intracellular IP3/ DAG (inositol trisphosphate/diacylglycerol) signaling pathway within the target cell.

The resulting sustained H1 receptor blockade leads to the modulation of system-level physiological effects associated with histamine release. Specifically, the inhibition of H1 signaling in vascular endothelium contributes to the reduced permeability of the vascular barrier. The intrinsic molecular half-life of the active metabolite contributes to prolonged receptor blockade, sustaining the mechanistic effect.

Advertisements

Dosage and Administration Information

How Dasselta 5 mg is Used: Official Administration Guidelines

Administration of Dasselta 5 mg follows established parameters regarding dosage, frequency, and route of intake. These guidelines define the standardized approach for using the medication.


Standard Dosing and Administration

Feature Official Instruction
Route of Administration Oral use.
Standard Adult Dose One 5 mg tablet once a day. (The maximum recommended dose.)
Dosing Frequency Once daily (every 24 hours).
Intake Condition May be taken with or without food.

The standard dose applies to adults and adolescents 12 years of age and over. The 5 mg film-coated tablet should be swallowed whole with water to ensure proper oral administration.


Duration and Special Population Rules

Usage patterns vary based on the type of allergic condition, though the 5 mg dose remains constant:

  • Intermittent Use: For symptoms that occur less than 4 days per week or for less than 4 weeks, treatment may be discontinued when symptoms are resolved and reinitiated upon their reappearance.
  • Persistent Use: For symptoms that occur 4 days or more per week and for more than 4 weeks, continuous use may be maintained during the period of allergen exposure.

Dose Adjustment for Impairment: For adult patients with severe hepatic (liver) or renal (kidney) impairment, a reduced starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.

Missed Dose Procedure: If a dose is missed, it should be taken as soon as possible. However, the patient must not take a double dose to compensate for the forgotten dose, but should return to the regular dosing schedule.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Dasselta 5 mg

This section provides a factual summary of the formal clinical research that has been conducted and evaluated for Desloratadine (Dasselta 5 mg). It outlines the types of studies available, the specific symptoms and outcomes research examined, and where the current evidence remains limited. This summary describes group patterns and research scenarios, not individual predictions or therapeutic claims.


Research Evidence for Allergic Rhinitis

The evidence base for Desloratadine in the clinical evaluation of symptoms associated with Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR) primarily comes from short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, such as those experienced during a period of high allergen exposure.

In these trials, the main focus was on patient-reported outcomes describing discomfort. Researchers monitored changes in symptom intensity, including measures of nasal symptoms like sneezing, running nose, and nasal itching, as well as associated ocular (eye) symptoms. The study populations mainly consisted of Adults and Adolescents (age 12 years and older). This evidence contributes to the broader evidence landscape and is documented as High quality by regulatory bodies for the endpoints measured during the stated short-term trial durations.

Research Evidence for Chronic Idiopathic Urticaria (Hives)

The evidence base for Desloratadine in the clinical evaluation of the skin symptoms of Chronic Idiopathic Urticaria (CIU), or persistent hives, was similarly conducted through randomized controlled trials. Studies were conducted to measure outcomes related to physical discomfort. Researchers specifically examined the value of pruritus (itching) severity scores and monitored the size and occurrence of wheals (hives). The trials also explored outcomes reflecting daily functioning or activity level, such as assessing sleep quality.

Long-Term Research and Study Duration

The foundational evidence for Dasselta 5 mg primarily comes from studies with follow-up durations that were limited, typically encompassing short, defined periods (e.g., 2 to 6 weeks). This means that while research provides insight into short-term changes, the full scope of sustained symptomatic measurement over many months or years is less systematically characterized by the primary RCT structure.

Research Gaps and Areas of Uncertainty

A key limitation is that many core studies compare the medicine against a placebo, meaning comparative evidence is lacking in direct head-to-head trials against all similar therapeutic options. Furthermore, research exploring outcomes in patients with comorbidities or other complex health profiles is often less systematic, and subgroup findings are uncertain in these areas.

Key Studies & References

  1. DESLORATADINE tablet, film coated (NIH DailyMed - Full Prescribing Information)
  2. Desloratadine (Oral Route) - Drug Information (MedlinePlus)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dasselta 5 mg (FAQ)


Q: Is Dasselta 5 mg used for both seasonal hay fever and year-round allergies?

A: Official product information confirms that Dasselta 5 mg is approved for managing symptoms related to both Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR). This indicates the medication is labeled for managing symptoms associated with allergies that occur only during certain seasons (hay fever) as well as those that persist year-round.

Q: Can Dasselta 5 mg provide relief for both nasal and ocular (eye) allergy symptoms?

A: Official clinical studies have evaluated the medication’s ability to relieve both nasal and non-nasal allergy symptoms. Evidence from this research indicates that Dasselta 5 mg is indicated to reduce symptoms associated with the eyes, such as itching, burning, and excessive tearing caused by allergies.

Q: How does the antihistamine mechanism in Dasselta 5 mg differ from older allergy medicines?

A: Dasselta 5 mg is classified as a highly selective peripheral H1 receptor antagonist. Official studies indicate the active substance is less likely to pass into the central nervous system compared to some older allergy medicines, supporting its non-sedating classification.

Q: Are there warnings about taking Dasselta 5 mg if a person has kidney or liver problems?

A: Regulatory documents note that the active substance is cleared from the body more slowly in individuals with severe hepatic (liver) or renal (kidney) impairment. For these specific patient groups, official regulatory guidance recommends a reduced dosing frequency due to the potential for slower clearance leading to higher systemic exposure.

Q: Can Dasselta 5 mg cause unusual emotional or psychological side effects like aggression or hallucinations?

A: Post-marketing surveillance has included reports of certain psychiatric effects. These types of adverse reactions, including reports of hallucinations, irritability, and aggression, have been reported in post-marketing experience, often with unknown or very rare frequency.

Q: What type of serious allergic reaction or symptom requires immediate medical attention while on Dasselta 5 mg?

A: Official safety information states that serious hypersensitivity reactions have been reported in post-marketing experience. These include severe reactions such as anaphylaxis (a severe, whole-body allergic reaction) and angioedema (swelling of the face, lips, or tongue). Symptoms like these are considered serious events that require immediate medical attention.

Q: What clinical trials or research themes are associated with desloratadine's use in children?

A: The Dasselta 5 mg tablet is not recommended for children under 12 years of age as safety and efficacy have not been established for this strength. However, the active ingredient is approved in lower strength oral solution forms for use in children starting from 6 months of age for allergic rhinitis, according to official labeling.

Q: What is the significance of the 5 mg strength of Dasselta?

A: The 5 mg strength is defined in official documents as the standard and maximum recommended daily dose for adults and adolescents. Regulatory studies have found that taking a dosage higher than 5 mg does not provide further therapeutic benefit for symptom relief but may be associated with an increased risk of adverse effects.

Q: Is Dasselta 5 mg an over-the-counter (OTC) drug, or does it require a prescription?

A: The official regulatory status of Dasselta 5 mg (prescription or over-the-counter) can vary depending on the country and specific product brand name. The active ingredient, desloratadine, is available in some non-prescription products in certain regions, while the 5 mg tablet strength is generally prescription-based.

Q: How is Dasselta (desloratadine) different from other common allergy medications like loratadine?

A: Official pharmacology information states that Desloratadine (Dasselta) is the primary, biologically active metabolite of the older antihistamine, loratadine. It is considered a more potent and selective peripheral H1 receptor antagonist.

Q: Does Dasselta 5 mg contain an ingredient that causes congestion relief (a decongestant)?

A: Official product labeling states that Dasselta 5 mg is a single-ingredient medicine containing only desloratadine. It is classified as an antihistamine and does not contain any ingredients intended to provide nasal congestion relief (a decongestant). Decongestants are added only in specific combination products.

Q: Is Dasselta 5 mg categorized as a steroid?

A: No, Dasselta 5 mg is officially categorized as a selective peripheral H1-receptor antagonist, which is the pharmaceutical classification for an antihistamine. It is not a steroid medication.

Q: What is the average time it takes for Dasselta 5 mg to start working?

A: Official studies examining the onset of action indicate that some individuals reported the start of symptom improvement as early as 1 hour and 15 minutes after taking a 5.0 mg dose. This evidence demonstrates symptom improvement can be observed relatively quickly.

Q: How long can the effects of one dose of Dasselta 5 mg be expected to last?

A: The medication is intended for once-daily use, and clinical evidence shows that the antihistaminic effects persist for the full 24-hour dosing interval. This duration is consistent with the drug's half-life, which describes how long the active substance remains in the body.

Q: Is Dasselta 5 mg safe for long-term daily use for chronic conditions?

A: Official guidelines define 'Persistent Use' for symptoms that occur four days or more per week and last longer than four weeks. This definition indicates continuous use may be considered during the period of allergen exposure. While the core research evidence is primarily from short-term trials, the long-term safety of the active ingredient is continuously monitored via post-marketing surveillance.

Q: Are there any reported links between Dasselta 5 mg use and weight gain or increased appetite?

A: Official safety documents report that appetite increased has been listed as a common adverse effect associated with the use of the drug. Additionally, weight increased has also been reported in post-marketing surveillance, although its frequency is often classified as not known or very rare.

Q: What are the gastrointestinal side effects commonly associated with Dasselta 5 mg?

A: Official product information indicates that common gastrointestinal side effects reported include dry mouth, dyspepsia (indigestion), and nausea. Other reported gastrointestinal symptoms include diarrhea and abdominal pain.

Q: Have there been reports of Dasselta 5 mg causing heart rhythm changes (QT prolongation)?

A: Regulatory reviews have investigated the potential for the active substance to cause a specific type of abnormal heart rhythm change known as QT interval prolongation. Based on the evidence, these reviews did not find evidence establishing a link between the use of desloratadine and this specific heart rhythm change.

Q: Does Dasselta 5 mg interact with common non-prescription pain relievers?

A: While the regulatory information does not list every non-prescription pain reliever, the product monograph notes that the co-administration with certain pain-relieving medications in the opioid class may lead to increased sedation. Reviewing all co-administered medications with a healthcare professional is standard practice.

Q: Can Dasselta 5 mg interact with other prescription medications a person might be taking?

A: Official regulatory data acknowledges several known interactions with other prescription medications, categorized as both moderate and minor. Official guidance emphasizes the importance of reviewing all prescription drugs currently being taken with a healthcare professional.

Q: Are there specific food items, like grapefruit, known to interact with Dasselta 5 mg?

A: Clinical pharmacology studies found that the absorption and bioavailability of the active substance are not significantly affected by ingestion with food or with specific fruit juices, including grapefruit juice. This is why the product is approved to be taken with or without a meal.

Q: Is Dasselta 5 mg generally suitable for use in the elderly population?

A: Official guidance states that adjusting the dosage of Dasselta 5 mg based purely on a person's advanced age is generally not necessary. However, if the person has severe kidney (renal) or liver (hepatic) impairment, a dose adjustment will be required regardless of age.

Q: What is the maximum duration for which a patient may take Dasselta 5 mg for seasonal allergies?

A: Official regulatory documents do not specify a hard cut-off for the maximum duration of use. Instead, they define usage based on the duration of symptoms as 'Intermittent' (less than four weeks) or 'Persistent' (four weeks or more), indicating that continuous use may be maintained during the period of allergen exposure, based on symptom presentation.

Q: Are there any instructions regarding cutting or crushing the Dasselta 5 mg tablet?

A: The administration instructions specify that the film-coated tablet should be swallowed whole with water. Official labeling advises against breaking, chewing, or crushing the tablet.

Q: Does Dasselta 5 mg have a known effect on blood pressure?

A: Regulatory information indicates that the single-ingredient 5 mg dose of desloratadine (Dasselta) does not typically have an effect on blood pressure. Concerns about blood pressure effects are generally associated with combination products that include a decongestant.

Q: Are there any known interactions between Dasselta 5 mg and herbal supplements?

A: The regulatory information for the class of antihistamines to which Dasselta belongs notes that there is limited clinical information on interactions with herbal supplements. Due to this lack of data, official guidance suggests caution regarding the co-administration of herbal products.

Q: Can Dasselta 5 mg cause hair loss or changes to skin appearance?

A: Official adverse reaction reports include dermatologic effects such as rash maculopapular (flat and raised red spots) and erythema (redness of the skin). Hair loss is not specifically listed among the reported side effects.

Q: Does Dasselta 5 mg affect the results of allergy skin tests?

A: Because of the way Dasselta works to block histamine, official clinical protocols generally recommend discontinuing the medication before any allergy skin testing is performed. Guidelines suggest stopping the medication for approximately five days prior to the test to prevent it from interfering with the accuracy of the results.

Advertisements

How should Dasselta 5 mg be stored and disposed of?

The official regulatory documentation for Dasselta 5 mg film-coated tablets specifies precise rules for storage, stability, and disposal to maintain product quality and safety.

Storage & Handling Requirements

Labeled Storage Temperature Requirements: No specific temperature range universally mandated (some regional labels may specify ambient room temperature).
Light/Moisture Protection Requirements: Must be stored in the original package to ensure protection from moisture.
Stability After Opening: For tablets packaged in a bottle (container), the shelf life after first opening is 3 months.
Child-Protection Storage: Must be kept out of the sight and reach of children as a mandatory safety measure.

Disposal Instructions

Disposal must follow pharmaceutical waste guidelines.

Disposal Method Restrictions: Medicines should not be disposed of via wastewater or household waste.
Handling of Unused Product: Patients must ask the pharmacist how to dispose of medicines no longer required to comply with local regulations.

These official statements define how the product must be stored, protected from environmental factors like moisture, and discarded safely without contaminating the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dasselta 5 mg found in:

A-Z Index: